Company overview
What does CERUS CORP do?
CERUS CORP (CERS) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3841 (Surgical & Medical Instruments & Apparatus).
What does CERUS CORP do?
CERUS CORP (CERS) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3841 (Surgical & Medical Instruments & Apparatus).
What industry is CERUS CORP in?
Healthcare · Surgical & Medical Instruments & Apparatus
What was CERUS CORP's latest reported revenue?
$57.4M for Q2 2026, from 10-Q filed Jul 30, 2026.
What changed in the latest comparable period?
Revenue increased +9.5% ($52.4M to $57.4M; Q2 2025 vs Q2 2026).
Business model (from the public record)
Belvedere describes the business using the issuer’s SEC classification and the company description extracted from public filings. Segment mix, customer identity, and recurring-versus-transactional revenue are shown only when those facts are identified in the filing extract—not inferred.
Healthcare · Surgical & Medical Instruments & Apparatus · United States
Financial profile
- Revenue
- $57.4M 10-Q · Q2 2026 · Filed Jul 30, 2026
- Revenue growth YoY
- +9.5% Belvedere calculation · 10-Q · Q2 2026 · Filed Jul 30, 2026
- Gross margin
- — Not identified in latest matched XBRL period
- Operating margin
- -3.2% Belvedere calculation · 10-Q · Q2 2026 · Filed Jul 30, 2026
- Net income
- -$2.9M 10-Q · Q2 2026 · Filed Jul 30, 2026
- Operating cash flow
- — Not identified in latest matched XBRL period
- Capex
- — Not identified in latest matched XBRL period
- Belvedere FCF
- — Not identified in latest matched XBRL period
- FCF margin
- — Not identified in latest matched XBRL period
- Cash
- $18M 10-Q · Jun 30, 2026 · Filed Jul 30, 2026
- Debt
- — Not identified in latest matched XBRL period
- Net debt
- -$18M Belvedere calculation · 10-Q · Jun 30, 2026 · Filed Jul 30, 2026
- Shares
- — Not identified in latest matched XBRL period
Balance sheet snapshot
Cash $18M. Identified debt —. Net debt -$18M. Missing debt tags are not treated as a zero-debt capital structure.
Financial information is derived from public filings and other identified sources. Belvedere calculations may differ from company-defined non-GAAP measures. See methodology and source notes. Valuation multiples are omitted because a licensed market-data provider is not configured.
Latest filings
| Form | Filed | Period | Accession | Source |
|---|---|---|---|---|
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | 0001193125-26-326295 | SEC |
| 8-K | Jul 30, 2026 | Jul 30, 2026 | 0001193125-26-326093 | SEC |
| 8-K | Jul 10, 2026 | Jul 6, 2026 | 0001020214-26-000015 | SEC |
| 8-K | Jun 8, 2026 | Jun 5, 2026 | 0001193125-26-261794 | SEC |
| 8-K | Jun 3, 2026 | Jun 2, 2026 | 0001193125-26-255488 | SEC |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | 0001193125-26-197777 | SEC |
| 8-K | Apr 30, 2026 | Apr 30, 2026 | 0001193125-26-197129 | SEC |
| DEF 14A | Apr 22, 2026 | Apr 22, 2026 | 0001020214-26-000011 | SEC |
| 8-K | Apr 21, 2026 | Apr 17, 2026 | 0001020214-26-000007 | SEC |
What changed
Each line is an arithmetic comparison of sourced facts. It is not a thesis.
Research view
Belvedere has not published an initiation or update on CERUS CORP. Universe inclusion is not a rating, a forecast, or coverage in the sell-side sense.
Research Radar
| Kind | Change | Explanation | Source | Date |
|---|---|---|---|---|
| Revenue | +9.5% | Revenue increased +9.5% ($52.4M to $57.4M; Q2 2025 vs Q2 2026). | 10-Q · RevenueFromContractWithCustomerExcludingAssessedTax | Jul 30, 2026 |
| Revenue acceleration | -14.6 pp | Quarterly revenue YoY growth moved from +24.1% to +9.5% (-14.6 percentage points). | 10-Q · BelvedereRevenueGrowthYoY | Jul 30, 2026 |
| Cash | $18.0M | Cash and cash equivalents were $18.0M as of the latest reported balance-sheet date. | 10-Q · CashAndCashEquivalentsAtCarryingValue | Jul 30, 2026 |
Rankings
- Healthcare Companies by Revenue Growth · rank 4 · +9.5%
Industry context
CERUS CORP is mapped to Healthcare (Surgical & Medical Instruments & Apparatus) from SIC metadata on the SEC submission. Mapping is a classification convenience, not a claim that every peer is economically comparable.
Belvedere Research Profile
This measures researchable information characteristics. It is not investment advice, a credit rating, or a buy/sell/hold recommendation.
Presence of core income-statement, cash-flow and balance-sheet concepts in SEC XBRL.
Comparable-period revenue history and operating-result availability.
Availability of margin, cash-flow and per-share concepts used in screening.
SEC periodic reports, current reports, proxy statement and website identified in submissions.
Distinct filing years in the current archive window plus comparable prior-period revenue.
Risks
Belvedere does not manufacture generic risk language. Material risks are those the issuer discloses in its periodic reports, particularly Item 1A of the latest Form 10-K.
A Form 10-K was not present in the current filing window.
Sources
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q2 2026
- Filed
- Jul 30, 2026
- Accession
- 0001193125-26-326295
- Concept
- RevenueFromContractWithCustomerExcludingAssessedTax
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q2 2026
- Filed
- Jul 30, 2026
- Accession
- 0001193125-26-326295
- Concept
- BelvedereRevenueGrowthYoY
(RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30 / RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30) - 1
View filing- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Jun 30, 2026
- Filed
- Jul 30, 2026
- Accession
- 0001193125-26-326295
- Concept
- CashAndCashEquivalentsAtCarryingValue
Disclosure
Belvedere Research publishes informational analysis. Nothing on this site is investment advice, an offer, or a solicitation to buy or sell any security.
This page is a company intelligence / data profile. It is not a research report unless a dated note is attached above. Rankings appearing here are independent of any issuer compensation.
Frequently asked questions
- What does CERUS CORP do?
- CERUS CORP (CERS) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3841 (Surgical & Medical Instruments & Apparatus).
- What industry is CERUS CORP in?
- CERUS CORP is classified in Healthcare (Surgical & Medical Instruments & Apparatus).
- When did CERUS CORP last file a periodic report?
- CERUS CORP last filed a 10-Q on Jul 30, 2026 (accession 0001193125-26-326295).
- What was CERUS CORP's latest revenue?
- $57.4M for Q2 2026, sourced from 10-Q filed Jul 30, 2026.
- Does Belvedere cover CERUS CORP?
- CERUS CORP is in the Belvedere universe. Presence in the universe is not the same as active initiation coverage.